Dual immunotherapy shows promising activity in high-risk early-stage HER2-negative breast cancer

A operation of 2 immunotherapy drugs showed encouraging enactment erstwhile added to modular chemotherapy fixed earlier country for patients with high-risk, early-stage HER2-negative bosom cancer, according to Phase II objective proceedings results from the ongoing I-SPY2 objective proceedings platform.